TuHURA Biosciences (HURA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Jul, 2026Executive summary
The annual meeting is scheduled for August 18, 2026, via virtual webcast, with stockholders able to vote online or by proxy as of the June 26, 2026 record date.
Key proposals include director elections, approval of share issuance under a credit facility, executive compensation, auditor ratification, and other business.
The board unanimously recommends voting in favor of all proposals, including a triennial say-on-pay frequency.
Voting matters and shareholder proposals
Six incumbent directors are nominated for election to serve until the 2027 annual meeting.
Approval is sought for issuing 1,878,287 shares to Parkview Holdings One LLC as a loan fee under a $50 million revolving credit facility, requiring shareholder approval under Nasdaq rules.
Advisory votes are requested on executive compensation and on holding future say-on-pay votes every three years.
Ratification of Cherry Bekaert LLP as independent auditor for 2026 is proposed.
Authorization to adjourn the meeting if necessary to solicit additional proxies is included.
Board of directors and corporate governance
The board consists of six members, with a majority qualifying as independent under Nasdaq rules.
Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent membership.
The board separates the roles of Chairman and President, and has adopted a Code of Ethics and an Insider Trading Policy.
All directors attended at least 75% of meetings in 2025.
Latest events from TuHURA Biosciences
- Virtual meeting to elect directors, approve share issuance, and ratify auditor on August 18, 2026.HURA
Proxy filing9 Jul 2026 - Shareholders will vote on director elections, share issuance, compensation, and auditor ratification.HURA
Proxy filing26 Jun 2026 - Clinical-stage immuno-oncology firm expands pipeline via merger, but faces ongoing financial and execution risks.HURA
Registration filing22 Jun 2026 - Diversified immuno-oncology pipeline advances amid ongoing losses and high funding needs.HURA
Registration filing22 Jun 2026 - Up to $250M in securities registered, including $50M ATM, to fund oncology pipeline and operations.HURA
Registration filing22 Jun 2026 - Merger completed, cash burn persists, and urgent funding needs threaten going concern.HURA
Q3 20249 Jun 2026 - Phase 3 IFx-2.0 trial and Kineta acquisition drive growth, backed by $36M in new funding.HURA
Q4 20249 Jun 2026 - Net loss widened to $6.7M in Q1 2025; pipeline and merger progress drive outlook.HURA
Q1 20259 Jun 2026 - Net loss rose to $7.1M in Q3 2025 as R&D spending increased and liquidity concerns persist.HURA
Q3 20259 Jun 2026